More articles from Radiopharmaceutical Therapy: Radioimmunotherapy

You have access
Anti-CD45 monoclonal antibody (MAb) dose optimization for astatine-211 (²¹¹At)-radioimmunotherapy (RIT) of relapsed non-Hodgkin lymphoma (NHL) in a canine model
Sofia Frost, Brian Miller, Tom Back, Erlinda Santos, Donald Hamlin, Oliver Press, Rainer Storb, D. Scott Wilbur, Brenda Sandmaier and John Pagel

Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 637;
You have access
Internal radiotherapy of ¹⁸⁸Re-IDA-D-[c(RGDfK)]₂ in combination with bevacizumab or temozolomide in U87-MG tumor-bearing mice
Byung Chul Lee, Jae Ho Jung, Byung Seok Moon and Sang Eun Kim

Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 636;
You have access
Anti-PSMA labeled liposomes loaded with Actinium-225 for potential antivascular alpha-radiotherapy
Charles Zhu, Amey Bandekar, Sangeeta Ray, Martin Pomper, Frank Bruchertseifer, Alfred Morgenstern and Stavroula Sofou

Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 640;
You have access
Treatment of bladder cancer with Bi-213-anti-EGFR-MAb - A pilot study
Klemens Scheidhauer, Christof Seidl, Alfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis, Michael Autenrieth, Florian Kurtz, Markus Essler, Markus Schwaiger and Reingard Senekowitsch-Schmidtke

Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 639;
You have access
Dose escalation of first in human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab
Ruby Meredith, Sui Shen, Patty Bunch, Michael Straughn, Julien Torgue and E. Banaga

Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 638;
You have access
Strong anti-tumor effect of ¹⁷⁷Lu-tetraxetan-tetulomab in nude mice with Ramos xenografts
Ada Repetto-Llamazares, Karianne Fleten, Sebastian Patzke, Roy Larsen and Jostein Dahle

Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 635;
You have access
Biodistribution and dosimetry of Lu-177 PSMA in metastasized castrate resistant prostate cancer patients
Christiane Schuchardt, Martina Weineisen, Stefan Wiessalla, Margret Schottelius, Harshad Kulkarni, Dirk Mueller, Ingo Klette, Hans Wester and Richard Baum

Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 641;
You have access
Enhancement of prostate-targeted radiotherapy using [131I]MIP-1095 in combination with radiosensitizing chemotherapeutic drugs
Mathias Tesson, Robert Mairs, Kevin Maresca, John Joyal and John Babich

Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 119;
You have access
Monitoring Lutetium-177-anti-CAIX radioimmunotherapy with In-111-anti-CAIX SPECT in an intraperitoneal clear cell renal cell carcinoma xenograft model
Constantijn Muselaers, Desiree Bos, Peter Mulders, Egbert Oosterwijk, Wim Oyen and Otto Boerman

Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 116;
You have access
Preclinical radioimmunotherapy of prostate cancer with 177Lu-11B6, a 177Lu-labeled monoclonal antibody specifically targeting free, unbound human kallikrein-related peptidase 2
Oskar Vilhelmsson Timmermand, Thuy Tran, Erik Larsson, Kim Pettersson, Hans Lilja, David Ulmert and Sven-Erik Strand

Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 118;

Main menu

User menu

Search

More articles from Radiopharmaceutical Therapy: Radioimmunotherapy

Pages